The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Prasugrel (Prasurel (5 mg)) is a platelet ...

DALLAS, TX — Long-term ischemic and bleeding risks climb with advancing age in elderly patients medically managed for acute coronary syndromes (ACS), as might be expected, but adding low-dose ...

"The company's first-to-file abbreviated new drug application (ANDA) of Prasugrel 5 mg and 10 mg tablets has been approved by the US Food and Drug Administration (USFDA)," Panacea Biotec said in a BSE ...

Global pharma major Lupin Limited announced that it has received United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA), Prasugrel Tablets USP, 5 ...

New Delhi, Oct 24 (PTI) Shares of Panacea Biotec today rose by over 4 per cent after the company said it has received final approval from the US health regulator to launch generic Prasugrel tablets, ...

Prasugrel (Prasulet (10 mg)) is a platelet aggregation inhibitor, prescribed for thrombotic cardiovascular (CV) events (life-threatening problems with the heart and blood vessels), in patients who had ...

A 5-mg dose of prasugrel compared with a 10-mg dose was associated with improvements in platelet response compared with clopidogrel in a cohort of older patients with stable CAD. Researchers evaluated ...

In low-weight patients with stable coronary artery disease (CAD), cutting the standard 10-mg dose of prasugrel in half provides platelet inhibition similar to that achieved with the normal dose in ...

“The company’s first-to-file abbreviated new drug application (ANDA) of Prasugrel 5 mg and 10 mg tablets has been approved by the US Food and Drug Administration (USFDA),” Panacea Biotec said in a BSE ...

with acute coronary syndrome, in the American market. The stock gained 4.21 per cent to close at Rs 248.95 on BSE. During the day, it zoomed 15.48 per cent to Rs 275.90. On NSE, shares of the company ...

Drug firm Panacea Biotec today said it has received final approval from the US health regulator to launch generic Prasugrel tablets, used for preventing blood clots in people with acute coronary ...